Viable cell compositions, and methods related to same
View Patent ↗Disclosed are viable cell compositions and related methods of preparation, maintenance and use. The viable cell composition can contain specified levels of cells, hydroxyethyl starch, and dimethylsulfoxide, and can be cryopreserved. The cryopreserved form of the composition can be thawed and combined with an aqueous liquid diluting medium to prepare a diluted viable cell composition that can contain specified, reduced levels of the dimethylsulfoxide and hydroxyethyl starch. The diluting medium can contain trehalose. The prepared, diluted viable cell composition can be administered to a patient.
1 . A method for treating a patient with viable uterine regenerative cells, comprising:
thawing a cryopreserved composition comprising viable uterine regenerative cells and a saline cryopreservation medium, wherein the saline cryopreservation medium of the cryopreserved composition consists of dimethylsulfoxide at a concentration of 2% and hydroxyethyl starch at a concentration of about 2% to about 10% producing a thawed viable uterine regenerative cell suspension;
combining an aqueous liquid diluting medium with the thawed viable uterine regenerative cell suspension in a volume ratio of at least 3:1 to produce a diluted viable uterine regenerative cell composition containing hydroxyethyl starch and dimethylsulfoxide, wherein the dimethylsulfoxide is present in the diluted viable uterine regenerative cell composition at a concentration of about 0.5% or less; and
administering the diluted viable uterine regenerative cell composition intravenously to the patient.
2 . The method of claim 1 , wherein the saline cryopreservation medium of the cryopreserved composition consists of dimethylsulfoxide at a concentration of 2% and hydroxyethyl starch at a concentration of about 4% to about 8%.
3 . The method of claim 1 , wherein the saline cryopreservation medium of the cryopreserved composition consists of dimethylsulfoxide at a concentration of 2% and hydroxyethyl starch at a concentration of about 6%.
4 . The method of claim 1 , wherein the viable uterine regenerative cells are viable human uterine regenerative cells.
5 . The method of claim 1 , wherein the viable uterine regenerative cells are viable canine uterine regenerative cells.
6 . The method of claim 1 , wherein the viable uterine regenerative cells are viable feline uterine regenerative cells.
7 . The method of claim 1 , further comprising, prior to thawing the cryopreserved composition, storing the cryopreserved composition at a temperature in the range of about −60° C. to about −100° C.
8 . The method of claim 1 , wherein the cryopreserved composition comprises viable uterine regenerative cells at a concentration of 10 million cells/mL.
9 . The method of claim 1 , wherein the patient is being treated for osteoarthritis.
10 . The method of claim 1 , wherein the patient is being treated for chronic renal failure disease.
11 . The method of claim 1 , wherein the patient is being treated for eczema.
12 . The method of claim 1 , wherein the patient is being treated for rheumatoid arthritis.
13 . The method of claim 1 , wherein the patient is being treated for polyarthritis.
14 . The method of claim 1 , wherein the patient is a human.
15 . The method of claim 1 , wherein the patient is a canine.
16 . The method of claim 1 , wherein the patient is a feline.
17 . The method of claim 1 , wherein the saline cryopreservation medium is a buffered saline solution.
18 . The method of claim 1 , wherein the saline cryopreservation medium is a phosphate buffered saline solution.
19 . The method of claim 1 , wherein the dimethylsulfoxide is present in the diluted viable uterine regenerative cell composition at a concentration of about 0.2%.
20 . The method of claim 1 , wherein the volume ratio of the aqueous liquid diluting medium to the thawed viable uterine regenerative cell suspension is 8:1.